Difei Yang
Stock Analyst at Mizuho
(1.98)
# 2,893
Out of 4,974 analysts
33
Total ratings
28.57%
Success rate
9.02%
Average return
Main Sectors:
Stocks Rated by Difei Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AKBA Akebia Therapeutics | Downgrades: Neutral | $6 → $2 | $2.96 | -32.43% | 4 | Mar 31, 2022 | |
| NVCR NovoCure | Maintains: Neutral | $229 → $200 | $12.28 | +1,528.66% | 6 | Jul 30, 2021 | |
| CASI CASI Pharmaceuticals | Initiates: Buy | $38 | $2.34 | +1,523.93% | 1 | Apr 26, 2021 | |
| FGEN FibroGen | Downgrades: Neutral | $725 | $12.11 | +5,886.79% | 4 | Apr 7, 2021 | |
| QURE uniQure | Upgrades: Buy | $52 | $17.95 | +189.69% | 4 | Apr 1, 2021 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $158 → $160 | $18.71 | +755.16% | 2 | Feb 26, 2021 | |
| XERS Xeris Biopharma Holdings | Maintains: Buy | $18 → $14 | $7.85 | +78.34% | 4 | Apr 23, 2020 | |
| NKTR Nektar Therapeutics | Upgrades: Buy | $315 → $525 | $40.18 | +1,206.62% | 4 | Feb 3, 2020 | |
| BOLD Boundless Bio | Upgrades: Buy | n/a | $1.14 | - | 2 | Aug 8, 2018 | |
| RGNX REGENXBIO | Initiates: Neutral | $28 | $9.71 | +188.36% | 1 | Feb 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.31 | +2,037.40% | 1 | Sep 27, 2017 |
Akebia Therapeutics
Mar 31, 2022
Downgrades: Neutral
Price Target: $6 → $2
Current: $2.96
Upside: -32.43%
NovoCure
Jul 30, 2021
Maintains: Neutral
Price Target: $229 → $200
Current: $12.28
Upside: +1,528.66%
CASI Pharmaceuticals
Apr 26, 2021
Initiates: Buy
Price Target: $38
Current: $2.34
Upside: +1,523.93%
FibroGen
Apr 7, 2021
Downgrades: Neutral
Price Target: $725
Current: $12.11
Upside: +5,886.79%
uniQure
Apr 1, 2021
Upgrades: Buy
Price Target: $52
Current: $17.95
Upside: +189.69%
Sarepta Therapeutics
Feb 26, 2021
Maintains: Buy
Price Target: $158 → $160
Current: $18.71
Upside: +755.16%
Xeris Biopharma Holdings
Apr 23, 2020
Maintains: Buy
Price Target: $18 → $14
Current: $7.85
Upside: +78.34%
Nektar Therapeutics
Feb 3, 2020
Upgrades: Buy
Price Target: $315 → $525
Current: $40.18
Upside: +1,206.62%
Boundless Bio
Aug 8, 2018
Upgrades: Buy
Price Target: n/a
Current: $1.14
Upside: -
REGENXBIO
Feb 13, 2018
Initiates: Neutral
Price Target: $28
Current: $9.71
Upside: +188.36%
Sep 27, 2017
Initiates: Buy
Price Target: $28
Current: $1.31
Upside: +2,037.40%